How Nordic Nanovector Stepped Back From The Abyss With APIM Merger
Picked Fellow Norwegian Firm After Multiple Talks
Five months after its lead drug Betalutin failed for follicular lymphoma, Nordic Nanovector has secured its future by teaming up with Trondheim-based APIM and gained access to its mid-stage investigational therapy for ovarian cancer, sarcoma and glioblastoma.
